Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Changes in the range of the medicinal herb Eriocaulon buergerianum Körnicke. (Eriocaulaceae) under climate change.

Xie YF, Yang L, Deng RY, Chen MH, Luan XF, Gottardi E, Zhang ZX.

Plant Biol (Stuttg). 2018 Jul;20(4):771-779. doi: 10.1111/plb.12836. Epub 2018 May 29.

PMID:
29683551
2.

CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Dogliotti I, Fava C, Serra A, Gottardi E, Daraio F, Carnuccio F, Giugliano E, Bocchia M, Saglio G, Rege-Cambrin G.

Stem Cell Investig. 2017 Jun 23;4:57. doi: 10.21037/sci.2017.06.02. eCollection 2017.

3.

Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.

Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G, Nicoli P, Gallo D, Bracco E, Morotti A, Panuzzo C, Gottardi E, Frassoni F, Saglio G, Cilloni D.

Oncotarget. 2016 Nov 8;7(45):74082-74096. doi: 10.18632/oncotarget.12269.

4.

Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.

Cerrano M, Crisà E, Gottardi E, Aguzzi C, Boccadoro M, Ferrero D.

Am J Hematol. 2016 Sep;91(9):E353. doi: 10.1002/ajh.24422. Epub 2016 Jun 20. No abstract available.

5.

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Review.

PMID:
27131622
6.

Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes.

Di Savino A, Gaidano V, Palmieri A, Crasto F, Volpengo A, Lorenzatti R, Scaravaglio P, Manello A, Nicoli P, Gottardi E, Saglio G, Cilloni D, De Gobbi M.

Br J Haematol. 2017 Feb;176(3):491-495. doi: 10.1111/bjh.13968. Epub 2016 Feb 23. No abstract available.

7.

Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.

Giona F, Moleti ML, De Benedittis D, Santopietro M, Nanni M, Testi AM, Orlando S, Iori AP, Piciocchi A, Gottardi E, Barberi W, Diverio D, Saglio G, Foà R.

Br J Haematol. 2016 Jun;173(5):749-53. doi: 10.1111/bjh.13991. Epub 2016 Feb 23.

PMID:
26913809
8.

Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.

Crivellaro S, Panuzzo C, Carrà G, Volpengo A, Crasto F, Gottardi E, Familiari U, Papotti M, Torti D, Piazza R, Redaelli S, Taulli R, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2015 Sep 22;6(28):25217-25. doi: 10.18632/oncotarget.4611.

9.

Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.

Koren-Michowitz M, Shimoni A, Daraio F, Crasto F, Lorenzatti R, Volchek Y, Amariglio N, Gottardi E, Saglio G, Nagler A.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1852-5. doi: 10.1016/j.bbmt.2015.06.018. Epub 2015 Jul 4.

10.

Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.

Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, Iaria G, Ladogana S, Burnelli R, Consarino C, Varotto S, Tucci F, Messina C, Nanni M, Diverio D, Biondi A, Pession A, Locatelli F, Piciocchi A, Gottardi E, Saglio G, Foà R.

Br J Haematol. 2015 Aug;170(3):398-407. doi: 10.1111/bjh.13453. Epub 2015 Apr 20.

PMID:
25891192
11.

Evaluation of function and structure of arterial wall in girls and young women with Turner syndrome.

Radetti G, Mazzanti L, Di Somma C, Salerno M, Gottardi E, Capalbo D, Tamburrino F, Colao A.

J Endocrinol Invest. 2015 Sep;38(9):963-70. doi: 10.1007/s40618-015-0268-9. Epub 2015 Apr 2.

PMID:
25833355
12.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A.

Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Review.

13.

Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia.

Giona F, Saglio G, Moleti ML, Piciocchi A, Rea M, Nanni M, Marzella D, Testi AM, Mariani S, Laurino M, Diverio D, Gottardi E, Foà R.

Br J Haematol. 2015 Jan;168(2):305-8. doi: 10.1111/bjh.13103. Epub 2014 Aug 27. No abstract available.

PMID:
25160793
14.

Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.

Iurlo A, Fracchiolla NS, Ferla V, Cassin R, Gottardi E, Beghini A, Gianelli U, Spinelli O, Cortelezzi A.

J Clin Oncol. 2014 Apr 1;32(10):e37-9. doi: 10.1200/JCO.2012.48.0665. Epub 2014 Jan 21. No abstract available.

PMID:
24449233
15.

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

Fava C, Rege-Cambrin G, Busca A, Gottardi E, Daraio F, Saglio G.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017. No abstract available.

PMID:
24290212
16.

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.

Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP.

BMC Cancer. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173.

17.

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.

Alimena G, Breccia M, Musto P, Cilloni D, D'Auria F, Latagliata R, Sanpaolo G, Gottardi E, Saglio G, Mandelli F.

Leuk Res. 2011 Apr;35(4):504-7. doi: 10.1016/j.leukres.2010.08.021. Epub 2010 Oct 23.

PMID:
20971509
18.

NPM1 deletion is associated with gross chromosomal rearrangements in leukemia.

La Starza R, Matteucci C, Gorello P, Brandimarte L, Pierini V, Crescenzi B, Nofrini V, Rosati R, Gottardi E, Saglio G, Santucci A, Berchicci L, Arcioni F, Falini B, Martelli MF, Sambani C, Aventin A, Mecucci C.

PLoS One. 2010 Sep 21;5(9):e12855. doi: 10.1371/journal.pone.0012855.

19.

Two heterologously expressed Planobispora rosea proteins cooperatively induce Streptomyces lividans thiostrepton uptake and storage from the extracellular medium.

Giardina A, Alduina R, Gottardi E, Di Caro V, Süssmuth RD, Puglia AM.

Microb Cell Fact. 2010 Jun 9;9:44. doi: 10.1186/1475-2859-9-44.

20.

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D.

J Clin Oncol. 2009 Nov 1;27(31):5195-201. doi: 10.1200/JCO.2009.22.4865. Epub 2009 Sep 14.

PMID:
19752335

Supplemental Content

Loading ...
Support Center